Barinthus Bio reports Q2 2026 results, completes VTP-1000 MAD enrollment

Barinthus Bio reported Q2 financial results and noted 42 planned subjects were enrolled in the Phase 1 AVALON trial for its celiac disease candidate, with data expected in Q4 2026. Additionally, the company completed enrollment for the MAD portion of the trial, signaling progress towards clinical data milestones.